Gilead Sciences
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $7,569,000 | $7,545,000 | $6,949,000 | $6,686,000 |
Gross Profit | 79,000 | 5,971,000 | 5,405,000 | 5,134,000 |
EBITDA | 2,451,000 | 1,884,000 | 2,983,000 | -3,541,000 |
EBIT | 1,194,000 | 2,289,000 | -4,231,000 | |
Net Income | 1,783,000 | 1,253,000 | 1,614,000 | -4,170,000 |
Net Change In Cash | 7,569,000 | 7,545,000 | 6,949,000 | 6,686,000 |
Free Cash Flow | 2,975,000 | 4,168,000 | 1,195,000 | 2,114,000 |
Cash | 5,037,000 | 2,772,000 | 4,718,000 | |
Basic Shares | 1,259,000 | 1,254,000 | 1,251,000 | 1,247,000 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $28,754,000 | $27,116,000 | $27,281,000 | $27,305,000 |
Gross Profit | 78,200 | 27,116,000 | 21,624,000 | 20,704,000 |
EBITDA | 1,662,000 | 7,605,000 | 8,852,000 | 11,329,000 |
EBIT | 7,605,000 | 6,749,000 | 9,279,000 | |
Net Income | 480,000 | 5,665,000 | 4,592,000 | 6,225,000 |
Net Change In Cash | 28,754,000 | 27,116,000 | 27,281,000 | 27,305,000 |
Cost of Revenue | 137,000 | -624,000 | ||
Free Cash Flow | 10,828,000 | 7,421,000 | 8,344,000 | 10,805,000 |
Cash | 6,085,000 | 5,412,000 | 5,338,000 | |
Basic Shares | 1,255,000 | 1,258,000 | 1,262,000 | 1,262,000 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | $1.90 |
2024-09-30 | $2.02 |
2024-06-30 | $2.01 |
2024-03-31 | -$1.32 |
